Tricyclic antidepressants, such as desipramine (Norpramin), doxepin, imipramine (Tofranil), nortriptyline (Pamelor) and protriptyline, and tetracyclic antidepressants, such as mirtazapine (Remeron).

Mirtazapine is a tetracyclic antidepressant that increases the amount of norepinephrine and serotonin in the brain through an unknown mechanism, possibly by presynaptic receptor inhibition ...

Anyone can experience depression no matter their sex, gender identity, or age. While it's more commonly diagnosed in women, more than 6 million men and people assigned male at birth in the U.S ...

Chang-Kung Chuang Institute, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China ...

tricyclic antidepressants, as well as cocaine and propranolol intoxication. Average age at the time of initial diagnosis or sudden death is 40 ± 22, with the youngest patient diagnosed at 2 days ...

So the two-- recurrent depression is the episodic type that comes in. I see it in waves in my head. It's this big wave that swells and then decreases. And it might go dormant for a while ...

Investing during a period of economic depression or recession can be daunting. However, choosing the right depression stocks can help you weather a period of uncertainty and protect your financial ...

More than 8.6 million people in England were prescribed an antidepressant in 2022-23 to treat their melancholy and the figures are rising. For those considering taking medication, read on.

You may be surprised if your healthcare provider recommends an antidepressant for chronic pain. Is this because she believes you are depressed? Or can antidepressants help with pain even for people ...

In a given year, an estimated 21 million adults in the United States will have at least one major depressive episode, which is 8.4% of U.S. adults. Many people with depression do not seek treatment, ...

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive.